

Global Skin Cancer Vaccine Market & Pipeline Insight 2015

<https://marketpublishers.com/r/GB717A0AAFDEN.html>

Date: February 2015

Pages: 179

Price: US\$ 1,500.00 (Single User License)

ID: GB717A0AAFDEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Skin cancer incidences are increasing at alarming rates across the world causing high morbidity and mortality. Research and development in field is expected to change the present scenario by providing better therapeutic options for patients. Skin cancer therapeutics available in market used for first-line treatment have modest efficacy which lays emphasis on the development of better products like skin cancer vaccines. Cancer vaccines for different disease indications have proved their worth in medical fraternity by providing better safety and efficacy profiles. Skin cancer vaccines based products are not available in market but they are soon expected to be entering in market in coming years. Market introduction of such products is much awaited to fulfill the unmet medical demand.

Skin cancer vaccine category seems to be one of the most advanced drug category in terms of number of products and types of products. Efforts in this field have allowed the investigators to come with new ideas like implants and oncolytic viruses for the treatment of skin cancer. Such dichotomy is not observable in other cancer categories due to which this segment is expected to occupy significant market share. Also, among different cancer products this skin cancer is expected to generate more revenues in coming years. Initially, it is expected that skin cancer vaccines would be used in combinatorial therapy with conventionally available drugs before becoming main stream treatment. Owing to better pharmacological profiles they are expected to become regular component of therapeutic regime.

Novelty of skin cancer vaccine design is expected to be the major factor in increasing their market penetration. Oncolytic skin cancer vaccines are much awaited products as

they have no competitors in present market. Theoretically, they can cure skin cancer at advanced stages and increase the life span of patients but they still needs to be investigated rigorously in clinical trials before market introduction. Skeptics and many medical professional show concern about use of oncolytic viruses as they have pathogenic background and mutate to wild type causing infection in patients. However, such phenomenon has not been observed due to advanced genetic engineering and strict quality control during skin cancer vaccine production. Some of these products are at advanced phases of clinical trials meeting predefine end points for qualifying as a viable pharmacological option.

Implant section of skin cancer vaccine is also expected to make significant impact by decreasing present mortality and morbidity rates. Concept and therapeutic products using implants for treatment has been in pharmaceutical market for several decades. They tend to be more comfortable, require less visits to physicians and higher cost arbitrage coupled with improved technological advancements. This gives a notion that skin cancer vaccines implants will get higher acceptance rates as compared to oncolytic virus based products. However, it should not be compared in case of pharmacological effects because this depends on patients' medical condition and oncologists' discretion to utilize best product according to necessity.

"Global Skin Cancer Vaccine Market & Pipeline Insight 2015" Report Highlight

Introduction to Skin Cancer Vaccine

Global Skin Cancer Vaccine Market Analysis

Global Skin Cancer Vaccine Pipeline by Company & Phase

Global Skin Cancer Vaccine Pipeline: 47 Vaccines

Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines

Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline)

Personalized Cancer Vaccines: Progress & Possibilities

Skin Cancer Vaccine Mechanism

Contents

1. INTRODUCTION TO CANCER VACCINES

2. CANCER VACCINES: MECHANISM & INNOVATIONS

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. INTRODUCTION TO SKIN CANCER VACCINE

4. SKIN CANCER VACCINE MECHANISM

5. GLOBAL SKIN CANCER VACCINE MARKET OVERVIEW

- 5.1 Current Market Scenario
- 5.2 Global Skin Cancer Vaccines Pipeline Overview

6. GLOBAL SKIN CANCER VACCINE MARKET DYNAMICS

- 6.1 Favorable Market Parameters
- 6.2 Commercialization Challenges

7. PERSONALIZED CANCER VACCINES: PROGRESS & POSSIBILITIES

8. GLOBAL SKIN CANCER VACCINES MARKET FUTURE PROSPECTS

9. GLOBAL SKIN CANCER VACCINE PIPELINE BY COMPANY & PHASE

- 9.1 Preclinical
- 9.2 Clinical
- 9.3 Phase-I
- 9.4 Phase-I/II
- 9.5 Phase-II
- 9.6 Phase-III

10. MARKETED SKIN CANCER VACCINES CLINICAL ANALYSIS

10.1 Melanoma Vaccine (MVax®, AVAX Technologies)

10.2 Melanoma Vaccine (Melacine®, GlaxoSmithKline)

11. SUSPENDED & DISCONTINUED SKIN CANCER VACCINES PIPELINE BY COMPANY & PHASE

11.1 No Development Reported

11.2 Discontinued

12. COMPETITIVE LANDSCAPE

12.1 Amgen

12.2 AVAX Technologies

12.3 Corixa

12.4 GlaxoSmithKline

12.5 Gradalis

12.6 Immunocore

12.7 Immune Design

12.8 Merck

12.9 MolMed

12.10 NeoStem Oncology

List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 3-1: Functions of Skin

Figure 3-2: Layers of Skin

Figure 3-3: Types of Skin Cancer

Figure 3-4: Factors Causing Skin Cancer

Figure 4-1: Types of Skin Cancer Treatment

Figure 4-2: Implantable Skin Cancer Vaccine

Figure 4-3: Mechanism of Oncolytic Skin Cancer Vaccine

Figure 4-4: Mechanism of T-VEC Skin Cancer Vaccine

Figure 5-1: Global Skin Cancer Vaccines Pipeline (%), 2015

Figure 5-2: Global Skin Cancer Vaccines Pipeline (Number), 2015

Figure 5-3: No Development Reported in Skin Cancer Vaccines Pipeline (%), 2015

Figure 5-4: No Development Reported in Skin Cancer Vaccines Pipeline (Number), 2015

Figure 5-5: Discontinued Skin Cancer Vaccines in Pipeline (%), 2015

Figure 5-6: Discontinued Skin Cancer Vaccines in Pipeline (Number), 2015

Figure 6-1: Drivers for Skin Cancer Vaccine

Figure 6-2: Skin Cancer Vaccine Market Challenges

Figure 7-1: Overview of Personalized Cancer Vaccines Development

Figure 7-2: Methodology for the Development of Personalized Cancer Vaccine

Figure 7-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine

I would like to order

Product name: Global Skin Cancer Vaccine Market & Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/GB717A0AAFDEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB717A0AAFDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970